MinMed To Conduct The First Modern Research On Mescaline In Switzerland
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), announced Thursday that it had obtained authorization from the local Swiss ethics committee to conduct the first clinical trial on mescaline.
